VRX up +3.88% percent Today $VRX High is at 142.10 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 18, 2014 at 10:44 AM

VRX up +3.88% percent Today $VRX High is at 142.10 and the Low 136.96 with current volume of 1,551,346.

Recent News posted below.

Valeant Pharmaceuticals International VRX other info.
http://investorshangout.com/Valeant-Pharmaceu...VRX-53038/

VRX Valeant Pharmaceuticals International Recent Headline News

Zoetis OK's stock buyback
Seeking Alpha - at Seeking Alpha - 18 mins ago

ZTS: 43.67 (-0.56), VRX: 142.14 (+5.41)

Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit?
Uncommon Profit Investor - at Seeking Alpha - 2 hrs 11 mins ago

AGN: 212.00 (+2.80), VRX: 142.14 (+5.41), ACT: 260.05 (+12.11)

Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation
PR Newswire - 2 hrs 43 mins ago
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Ideal Implant Incorporated today announced the receipt of approval from the U.S. Food and Drug Administration (FDA) and Health Canada to market the IDEAL IMPLANT® Saline-filled Breast Implant for use in primary breast augmentation or replacement of existing augmentation implants. The FDA approval of the IDEAL IMPLANT was based on an extensive review of various studies and data including a U.S. clinical trial that began in 2009 with 45 plastic surgeons and 502 women, who underwent breast augmentation or replacement of augmentation implants. The clinical trial is on-going and will continue to provide follow-up data through 2020.
VRX: 142.14 (+5.41), VRX.TO: 160.74 (+6.34)

Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 212.00 (+2.80), ACT: 260.07 (+12.13), VRX: 142.14 (+5.41), V: 250.17 (+0.37), ALXN: 189.99 (+3.21), CTSH: 53.00 (-0.06), MA: 83.46 (+0.26), ADS: 282.52 (+1.64)

Business Highlights
By The Associated Press - AP - Mon Nov 17, 4:57PM CST
___
VRX: 142.14 (+5.41), HAL: 49.77 (+0.54), GOOGL: 551.58 (+4.94), GOOG: 540.64 (+4.13), NRG: 31.74 (+0.06), VRX.TO: 160.74 (+6.34)

Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 212.00 (+2.80), ACT: 260.07 (+12.13), VRX: 142.14 (+5.41), MRK: 59.72 (+0.26), VRX.TO: 160.74 (+6.34)

Stocks End Mixed As Allergan Jumps On Actavis Deal
at Investor's Business Daily - Mon Nov 17, 3:16PM CST
Major averages pared losses from a late-morning slump to end mixed amid big merger deals and weak economic data. The S&P 500 and Dow Jones industrial average closed fractionally higher, while the Nasdaq fell 0.4%. Volume ran lower across the board in...
AGN: 212.00 (+2.80), VRX: 142.14 (+5.41), ACT: 260.07 (+12.13), SAFM: 86.84 (+1.91), PPC: 31.29 (+0.35), MIK: 21.69 (+0.04), TSN: 42.76 (-0.27)

Stock Market Today: Japan Recession Keeps Markets From Celebrating Deals Deluge
at The Street - Mon Nov 17, 3:15PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies momentarily distracts Wall Street from worrying news Japan has fallen into recession in its third quarter.
AMZN: 328.05 (+5.00), HAS: 55.99 (-0.38), ACT: 260.07 (+12.13), VRX: 142.14 (+5.41), JIVE: 6.38 (+0.01), FB: 74.39 (+0.15), HAL: 49.77 (+0.54), DWA: 22.25 (-0.06), AGN: 212.00 (+2.80), LNKD: 222.84 (-0.44), BHI: 65.95 (+0.72), CRM: 63.15 (+0.64)

Stocks Mixed In Afternoon; Allergan Jumps To New High
at Investor's Business Daily - Mon Nov 17, 2:13PM CST
Stocks remained mixed late Monday afternoon as investors weighed a spate of merger activity against news that Japan fell into a recession. The Dow Jones industrial average and the S&P 500 were each up 0.1%, while the Nasdaq was down 0.3%. Volume was...
AGN: 212.00 (+2.80), VRX: 142.14 (+5.41), ACT: 260.06 (+12.12), LNKD: 222.84 (-0.44), FB: 74.39 (+0.15), HAL: 49.77 (+0.54), BHI: 65.95 (+0.72), Z: 119.50 (+1.64)

OK, so it's not Allergan
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 12:36PM CST

VRX: 142.14 (+5.41)

Stock Market Today: Stocks Are Mixed as Corporate Deals Offset Japan's Recession
at The Street - Mon Nov 17, 12:16PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies distract Wall Street from worrying news Japan had fallen into recession in its third quarter.
AGN: 212.00 (+2.80), HAS: 55.99 (-0.38), AMZN: 328.05 (+5.00), VRX: 142.14 (+5.41), ACT: 260.06 (+12.12), LNKD: 222.84 (-0.44), JIVE: 6.38 (+0.01), FB: 74.39 (+0.15), HAL: 49.78 (+0.55), DWA: 22.25 (-0.06), CRM: 63.15 (+0.64), BHI: 65.97 (+0.74)

Pershing Square wins big on Actavis buy
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:22AM CST

AGN: 212.00 (+2.80), ACT: 260.06 (+12.12), VRX: 142.14 (+5.41)

Today's Unusual Social Activity Stock: Valeant Pharmaceuticals International (VRX)
at The Street - Mon Nov 17, 10:36AM CST
Trade-Ideas LLC identified Valeant Pharmaceuticals International (VRX) as an unusual social activity candidate
VRX: 142.14 (+5.41)

Allergan's $66 Billion Actavis Deal is Still a Win for Bill Ackman
at The Street - Mon Nov 17, 9:59AM CST
Valeant says it can't justify $219 a share offer to shareholders.
ZTS: 43.66 (-0.57), AGN: 212.00 (+2.80), VRX: 142.14 (+5.41), ACT: 260.06 (+12.12)

Actavis Nabs Allergan For $66 Billion; Valeant Folds
at Investor's Business Daily - Mon Nov 17, 9:17AM CST
One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in...
AGN: 212.00 (+2.80), VRX: 142.14 (+5.41), ACT: 260.06 (+12.12)

Time to move on: Valeant chief says $219 too rich
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 9:13AM CST

ACT: 260.06 (+12.12), VRX: 142.14 (+5.41)

Valeant Comments On Allergan Announcement
PR Newswire - Mon Nov 17, 8:29AM CST
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock.
AGN: 212.00 (+2.80), ACT: 260.06 (+12.12), VRX: 142.14 (+5.41), VRX.TO: 160.74 (+6.34)

Stock Futures Set For Weak Open; Halliburton, Baker Hughes Merge
at Investor's Business Daily - Mon Nov 17, 8:12AM CST
Stock futures pointed modestly lower ahead of Monday's open as merger news stirred some of the most notable premarket stock moves. Dow futures sifted 27.7 points below fair market value. Nasdaq 100 futures were 9.1 points lower, and S&P 500 futures...
AGN: 212.00 (+2.80), HAS: 55.99 (-0.38), VRX: 142.14 (+5.41), ACT: 260.06 (+12.12), HAL: 49.78 (+0.55), DIS: 90.57 (+0.16), DWA: 22.25 (-0.06), BHI: 65.98 (+0.75)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Kentucky Power's Bold Plan to Boost Local Economy

Electricity, Economy, and Execution Kentucky Power just laid out plans that could massively swing the pendulum for eastern Kentucky's economic prospects. They've put filings on the table for the Kentucky Public Service Commission that, if approved, promise big economic benefits. We're talking about a potential infusion of $500 million through fixed-rate offsets and an...

KeyCorp Plans Redemption of Series E Preferred Stock

KeyCorp Drops a Major Redemption Bombshell Out of the blue, KeyCorp (NYSE: KEY) just tossed a curveball at investors with the announcement they’re redeeming every last one of their Series E Fixed-to-Floating Rate Perpetual Non-Cumulative Preferred Stock shares come December 15, 2026. This move is bound to stir the pot a bit even if you’ve been around the block a few...

El Pollo Loco Faces Class Action Over Wage Practices

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Manhattan Associates Faces Investigation by KSF Law Firm

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

BIBIBOP Brings Good Vibes with OLIPOP Happy Hour

Boosting Midday Energy with BIBIBOP's New Promo Here we go, folks. BIBIBOP Asian Grill is dialing up the culinary energy just when you need it most. From November 16 to 22, during their Good Energy Happy Hour, they’re serving up a deal designed to pump some pep into your afternoon—free OLIPOP prebiotic soda with any regular bowl purchase. Just stroll into any of their...

FiEE Rockets to Profitability with 382% Revenue Surge

Big Moves in the Tech Jungle: FiEE's Comeback Let's chew the fat on FiEE, Inc., a company that's left its hardware-heavy past in the dust and grabbed the bull by the horns with fresh, AI-driven brand tech solutions. We're talking a whopping 382.1% revenue increase. Now, that's not chump change. From barely scraping $2 million last year to raking in $9.6 million just for...

Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...